MICROWAVE ABLATION (MWA)
ADVANCED TUMOR ABLATION

Microwave ablation heats tissue through dielectric heating — polar water molecules attempt to align with a rapidly oscillating electromagnetic field (billions of times per second), generating rotational friction and heat throughout the irradiated volume. This fundamentally differs from RFA, which relies on ionic agitation at the electrode surface.

“MWA deposits energy throughout the tissue volume — not just at the probe surface. This is why it overcomes the heat-sink effect that limits RFA near blood vessels.”

• Dielectric Heating Mechanism

  At 2.45 GHz (standard globally) or 915 MHz (USA), water molecules in tissue cannot keep pace with the oscillating electric field — rotational friction generates intense heat throughout the irradiated volume. Because energy deposition is proportional to water content (~70-80% in biological tissue), heating is rapid and intense throughout the entire ablation zone.

• Higher Temperatures than RFA

  MWA achieves ablation temperatures of 60-150 degrees C compared to 60-100 degrees C for RFA. The higher temperature ceiling enables faster cell death, larger ablation zones, and effective ablation of tissues with low electrical conductivity where RFA underperforms.

• Heat-Sink Effect Resistance

  Blood flow through nearby vessels cools the tissue adjacent to the vessel during RFA — leaving viable tumor cells near the vessel wall. Because MWA deposits energy volumetrically rather than conductively, it is significantly less affected by vascular cooling. This is the central clinical advantage of MWA over RFA for perivascular hepatic tumors.

• China MWA Innovation

  Chinese-designed MWA systems (ECO Microwave, Vison Blue from PLA General Hospital) represent some of the most technically advanced clinical MWA platforms globally. Multi-antenna simultaneous activation enables ablation zones of 6-8 cm — not achievable with single-antenna RFA — enabling treatment of large HCCs previously requiring surgery.

MWA and RFA are both thermal ablation modalities, but their physical mechanisms produce important clinical differences in specific situations.

MWA has an established evidence base across multiple solid tumor types. Its advantage over RFA is most pronounced for perivascular, larger, and difficult-to-access lesions.

• Hepatocellular Carcinoma (HCC)

  Multiple RCTs comparing MWA vs RFA in HCC less than 5 cm show equivalent or superior overall survival with MWA, shorter procedure times, and higher complete ablation rates for perivascular tumors. For HCC 3-5 cm, MWA combined with TACE (TACE-MWA) is the standard approach at Chinese hepatobiliary centres. MWA is used as a bridge to transplant and for recurrence after prior ablation.

• Colorectal Liver Metastases (CRLM)

  MWA for CRLM achieves local tumor progression rates comparable to surgery for lesions less than 3 cm and is the standard ablative modality for non-resectable CRLM at leading Chinese and Indian hepatobiliary centres. Multi-antenna simultaneous activation enables treatment of multiple lesions per session.

• Lung Cancer (NSCLC and Pulmonary Metastases)

  CT-guided percutaneous MWA for early-stage NSCLC in non-surgical candidates achieves 2-year local tumor control rates of 70-85%. For pulmonary metastases from CRC, RCC, and sarcoma, MWA is preferred over RFA due to reduced heat-sink effect from adjacent pulmonary vessels and better performance in aerated lung tissue.

• Renal Cell Carcinoma and Other Kidney Tumors

  Percutaneous MWA for T1a RCC (less than 4 cm) achieves 5-year recurrence-free survival rates of 90%+ comparable to partial nephrectomy, with preservation of renal function. Preferred over RFA for posterior and hilar tumors where the heat-sink effect from renal vessels limits RFA efficacy.

• Thyroid Nodules and Adrenal Tumors

  Ultrasound-guided MWA for benign thyroid nodules achieves 50-80% volume reduction at 12 months — a non-surgical alternative for symptomatic thyroid nodules in patients who decline or are unfit for surgery. For adrenal metastases and primary adrenal tumors, CT-guided MWA offers effective local control.

• 95%+Complete ablation rate for HCC less than 3 cm with MWAComparable to surgical resection for small HCC in patients with adequate liver function.
• 6-8 cmMaximum ablation zone with multi-antenna MWAChinese-designed simultaneous multi-antenna systems enable treatment of large tumors previously requiring surgery.
• 5-10 minTypical MWA procedure time per lesionSignificantly faster than RFA (15-30 min per lesion) — reducing anaesthesia time and enabling multi-lesion treatment.
• 55%of world HCC burden is in ChinaChina has the highest volume of MWA procedures globally — driven by the enormous HBV-related HCC burden.
• 84.6%3-year local tumor progression-free survival with MWAIn a comparative study of HCC within the Milan criteria, MWA achieved strong local control, reinforcing its role as a curative local therapy for selected small liver tumors.
• 2.6–4.6%Major complication rate after liver MWAPublished reviews report a low major complication rate, supporting MWA’s minimally invasive safety profile when performed in experienced centers.

From eligibility assessment to treatment at high-volume MWA centres — end-to-end navigation for international patients.

1. 1

   Case Review and MWA Eligibility

   Review of imaging (CT/MRI), liver function tests, tumour characteristics (size, location, relationship to vessels), and treatment history to determine whether MWA, RFA, TACE-MWA combination, or surgical resection is the most appropriate treatment.

2. 2

   Centre Matching

   Zhongshan Hospital Shanghai, EHBH Shanghai, and Fudan University Shanghai Cancer Centre for liver MWA. Peking University Cancer Hospital for multi-organ MWA. Tata Memorial Centre Mumbai and Apollo Hospitals for Indian centre access.

3. 3

   Remote Multidisciplinary Review

   Interventional radiology and hepatology MDT review of imaging before travel — confirming MWA suitability and providing a preliminary treatment plan including number of sessions and combination strategy.

4. 4

   Travel and Logistics

   MWA is typically a same-day or 1-2 day admission procedure. Multiple sessions may be required for multiple lesions. CancerFax arranges medical visa, accommodation, and in-country support for the full treatment course.

5. 5

   Follow-Up Imaging Coordination

   Post-ablation CT or MRI at 4-6 weeks assesses treatment response using mRECIST criteria. CancerFax coordinates remote review of follow-up imaging and supports the decision on need for repeat ablation or complementary treatment.

Each page covers one microwave ablation topic in depth.

Frequently Asked Questions